Skip to main content
SpringerLink
Log in

DDW-Kongress in San Diego CA — Teil 3

UpToDate bei Kolon, Mikrobiom und CED

  • aktuell
  • Published:
Gastro-News Aims and scope

Auf dem amerikanischen Gastroenterologie-Kongress (DDW, Digestive Disease Week), der 2019 in San Diego CA stattfand, erfuhren mehr als 14.000 Teilnehmer alles über aktuelle Standards, Neuigkeiten und wissenschaftliche Erkenntnisse zu Kolon, Mikrobiom und chronisch entzündlichen Darmerkrankungen. In einer Serie von Artikeln werden in GASTRO NEWS die Inhalte der wichtigsten Vorträge und Abstracts präsentiert.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. Tabung FK et al. J Nutr 2017;147:1567–77

    Article  CAS  Google Scholar 

  2. Ma W et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1595

    Google Scholar 

  3. Nguyen LH et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1875

    Google Scholar 

  4. Taneja SL et al. Gastroenterology 2019;156(6) Suppl 1: OP 838

    Google Scholar 

  5. Ciezki KJ et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Mo1627

    Google Scholar 

  6. Chang SH et al. Gastroenterology 2019;156(6) Suppl1: Abstract Mo1717

    Google Scholar 

  7. Fritscher-Ravens A et al. Gastroenterology 2019;156(6) Suppl1: OP946

    Google Scholar 

  8. Heyde S et al. Gastroenterology 2019, 156(6) Suppl1: Abstract Su1625

    Google Scholar 

  9. Garcia-Zermeno KR et al. Gastroenterology 2019;156(6) Suppl1: Abstract Sa1658

    Google Scholar 

  10. Leite G JH et al. Analysis of the small intestinal microbiome reveals marked differences from stool microbiome in a large scale human cohort: redefining the „gut microbiome.“ Gastroenterology 2019;156(6) Suppl 1: Abstract Sa1911

    Google Scholar 

  11. Haydek JP et al. Differences among luminal and mucosal microbiota among fecal microbiota transplant recipients. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1863

    Google Scholar 

  12. Villanueva-Millan M et al. Deep sequencing of the entire human small intestine: a comparison to stool microbiome in the REIMAGINE study. Gastroenterology 2019;156(6) Suppl1: Abstract Sa1909

    Google Scholar 

  13. Jin G et al. Intestine microbiome aspiration (IMBA) capsule: a new autonomous and minimally-invasive device for whole gut microbiome sampling and mapping. Gastroenterology 2019;156(6) Suppl1: OP977

    Google Scholar 

  14. Stallmach A et al. Long-term multidonor fecal microbiota transfer (FMT) by oral capsules for active ulcerative colitis. Gastroenterology 2019;156(6) Suppl1: OP1129

    Google Scholar 

  15. Ott SJ et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology 2017; 152(4):799–811

    Article  Google Scholar 

  16. Phillips L et al. Marked Alterations in the viral genome in patients with recurrent Clostridium difficile infection before and after fecal microbiota transplant. Gastroenterology 2019;156(6) Suppl 1: OP426

    Google Scholar 

  17. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-aboutpotential-risk-serious-infections-caused-multi-drug-resistant-organisms

  18. Cammarota G, Ianiro G, Tilg H et al. (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569–580

    Article  Google Scholar 

  19. Borren N et al. Impact of biologic therapy on resolution of fatigue symptoms in patients with active inflammatory bowel disease: a prospective cohort study. Gastroenterology 2019; 156(6): Sa1861

    Google Scholar 

  20. Borren N et al. Gut microbial dysbiosis contributes to fatigue in patients with quiescent inflammatory bowel diseases. Gastroenterology 2019; 156(6) Suppl 1: OP146.

    Google Scholar 

  21. Narula N et al. Risk of infectious complications from medical therapies in post-surgical patients. Gastroenterology 2019; 156(6) Suppl1: OP 640

    Google Scholar 

  22. Cohen BL et al. Anti-tumor necrosis factor therapy is not associated with postoperative infection: results from prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for post-operative infection (PUCCINI). Gastroenterology 2019; 156(6) Suppl1: OP 415a

    Google Scholar 

  23. Sands B et al. Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: week 44 results from UNIFI. Gastroenterology 2019; 156(6) Suppl1: OP 833

    Google Scholar 

  24. Sands B et al. Efficacy in biologic failure and nonbiologic failure populations in a phase 3-study of ustekinumab in moderate-severe ulcerative colitis: UNIFI. Gastroenterology 2019; 156(6) Suppl1: OP 833a

    Google Scholar 

  25. Sands B et al. Characterization of patients with delayed response to ustekinumab for Crohn’s disease. Gastroenterology 2019; 156(6) Suppl1: Tu 1725

    Google Scholar 

  26. Sands B et al. Vedolizumab shows superior efficacy versus adalimumab: results of VARSITY - the first head-to-head Study of biologic therapy for moderate to severe ulcerative colitis. Gastroenterology 2019; 156(6) Suppl1: LB Abstract 416a

    Google Scholar 

  27. Dubinky M et al. Measuring the mediating effects of tofacitinib on health status in ulcerative colitis: data from the OCTAVE program. Gastroenterology 2019; 156(6) Suppl1: Sa 1872

    Google Scholar 

  28. Chiorean MV et al. Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. Gastroenterology 2019; 156(6) Suppl1: OP 798

    Article  Google Scholar 

  29. Hanes L et al. Gastroenterology 2019; 156(6) Suppl1: OP179

    Google Scholar 

  30. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RI/2019/RI-xeljanz.html, abgerufen am 12.10.2019.

  31. Sugimoto K et al. Highly bioavailable curcumin (Theracurmin) for Crohn’s disease: randomized, multicenter, double-blind, placebo-controlled trial. Gastroenterology 2019; 156(6) Suppl1: Abstract Tu1716

    Google Scholar 

  32. Chandan S et al. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and metaanalysis of clinical trials. Gastroenterology 2019; 156(6) Suppl1: Abstrac Su1871

    Article  Google Scholar 

Quelle

  • Digestive Disease Week (DDW) 18. – 21. Mai 2019 San Diego CA, USA

Download references

Author information

Authors and Affiliations

  1. GFO Klinikum Bonn, St. Josef Hospital Bonn-Beuel, Hermannstraße 37, 53225, Bonn, Deutschland

    Birgit Terjung

  2. Internistisches Klinikum München Süd, Am Isarkanal 36, 81379, München, Deutschland

    Manfred Gross (gross@ikms.de)

Authors
  1. Birgit Terjung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manfred Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Birgit Terjung.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Terjung, B., Gross, M. UpToDate bei Kolon, Mikrobiom und CED. Gastro-News 6, 57–62 (2019). https://doi.org/10.1007/s15036-019-0698-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-019-0698-x

Search

Navigation